Key result
Variable antithrombotic prevention protocols based on individual criteria and adjusted by anti-Xa monitoring are proposed for critically ill patients, though kit standardization remains lacking.
Why the study?
Traditional thromboprophylaxis protocols are frequently ineffective in ICU patients due to extreme individual variability, leaving unresolved questions regarding dosing frequency, anti-Xa monitoring timing, therapeutic targets, and assay standardization.
Does variable antithrombotic prophylaxis adjusted by anti-Xa monitoring improve venous thromboembolism prevention in critically ill patients?
Does variable antithrombotic prophylaxis adjusted by anti-Xa monitoring improve venous thromboembolism prevention in critically ill patients?
Thromboprophylaxis in intensive care is critical but frequently ineffective with standard dosing, highlighting a need for individualized, weight-based protocols guided by anti-Xa monitoring.
Tailored anti-Xa-guided protocols remain investigational in critically ill patients; leaves open kit standardization and prospective outcome trials.
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is an important complication in patients hospitalized in intensive care units (ICU). Thromboprophylaxis is mainly performed with Low Molecular Weight Heparin (LMWH) and, in some specific patients, with Unfractionated Heparin (UFH). These intensive units are an environment where individual patient variability is extreme and where traditional antithrombotic protocols are frequently ineffective. This was known for a long time, but the hospitalization of many patients with COVID-19 inflammatory storms suddenly highlighted this knowledge. It is therefore reasonable to propose variable antithrombotic prevention protocols based initially on a series of individual criteria (weight, BMI, and thrombotic risks). Secondly, they should be adjusted by the monitoring of anticoagulant activity, preferably by measuring the anti-Xa activity. However, we still face unresolved questions, such as once- or twice-daily LMWH injections, monitoring at the peak and/or trough, and poorly defined therapeutic targets. Equally surprisingly, we observed a lack of standardization of the anti-Xa activity kits.
No takes yet. Share an insight, caveat, or question.
Cauchie et al. (2021) conducted a review in Critically ill patients at risk for venous thromboembolism. Thromboprophylaxis (LMWH or UFH) with anti-Xa monitoring was evaluated. Variable antithrombotic prevention protocols based on individual criteria and adjusted by anti-Xa monitoring are proposed for critically ill patients, though kit standardization remains lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: